Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 20, 2023

Momelotinib vs Danazol in Symptomatic Patients With Anaemia and Myelofibrosis Previously Treated With a JAK Inhibitor

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
Lancet Haematol 2023 Jul 27;[EPub Ahead of Print], AT Gerds, S Verstovsek, AM Vannucchi, HK Al-Ali, D Lavie, AT Kuykendall, S Grosicki, A Iurlo, YT Goh, MC Lazaroiu, M Egyed, ML Fox, D McLornan, A Perkins, SS Yoon, V Gupta, JJ Kiladjian, N Granacher, SE Lee, L Ocroteala, F Passamonti, CN Harrison, S Oh, BJ Klencke, J Yu, R Donahue, J Kawashima, R Mesa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading